Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

(2013) A. López-Ferrer et al.   BRITISH JOURNAL OF DERMATOLOGY

Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy

(2012) Gregorio Carretero   ARCHIVES OF DERMATOLOGY

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

(2012) M.H.A. Rustin   BRITISH JOURNAL OF DERMATOLOGY

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update

(2012) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

(2012) Howa Yeung et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

(2012) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Drug survival rates for tumour necrosis factor-α antagonists in psoriasis

(2011) A.D. Burden   BRITISH JOURNAL OF DERMATOLOGY

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

(2011) A.M.G. Brunasso et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Adherence in the Treatment of Psoriasis: A Systematic Review

(2011) M. Augustin et al.   DERMATOLOGY

Registerforschung in der Dermatologie

(2011) S.J. Rustenbach et al.   HAUTARZT

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE

(2011) J.-P. Ortonne et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

(2010) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

(2010) Robert Bissonnette et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab treats psoriasis in patients previously treated with etanercept: A case series

(2009) Paul S. Yamauchi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation

(2009) CL Martyn-Simmons et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data

(2009) Daniel Aletaha   ARTHRITIS RESEARCH & THERAPY

Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

(2009) Amr A Saad et al.   ARTHRITIS RESEARCH & THERAPY

Sustained Efficacy and Safety of Adalimumab in Psoriasis Treatment: A Retrospective Study of 49 Patients With and Without a History of TNF-α Antagonist Treatment

(2008) Livia Van et al.   ARCHIVES OF DERMATOLOGY